Frontiers reaches 6.4 on Journal Impact Factors
The rheumatology specialty section of Frontiers in Medicine publishes the latest insights in the mechanisms of disease, new biomarkers, clinical epidemiology and new treatment perspectives of rheumatic diseases, with the aim of helping clinical rheumatologists to achieve better patient’s individual outcomes. We also aim at promoting basic, translational and clinical research, engaging clinicians and scientist in the common goal of expanding the rheumatology frontiers of knowledge.
In the past few decades, we witnessed a revolution in the care of patients with rheumatic conditions. A better understanding of the physiopathology of this heterogeneous group of diseases paved the way for novel treatments and more aggressive treatment strategies. Particularly for inflammatory rheumatic diseases, remission became the treatment goal. Nevertheless, most patients with chronic joint inflammatory conditions still suffer from a disease that is debilitating and unremitting, as only few patients attain sustained remission. In addition, pathologies such as scleroderma and osteoarthritis still lack true disease-modifying treatments. Finally, the management of common diseases, such as osteoporosis, back pain and periarticular soft tissue conditions, remains an open field for the development of new evidence-based treatment strategies. Therefore, despite noticeable progress, rheumatology is still a medical area with many ongoing challenges.
Contrary to other fields of medicine, such as cardiology or oncology, early diagnostic and prognostic markers and predictors of treatment response are lacking in rheumatology. Stratification of patients and treatment profiling remains distant from rheumatology daily practice. Rheumatology has to find its way through various aspects of research that would lead to the eventual adaptation of a precision medicine approach for treating patients with rheumatic disorders.
The rheumatology specialty section of Frontiers in Medicine publishes the latest insights in the mechanisms of disease, new biomarkers, clinical epidemiology and new treatment perspectives of rheumatic diseases, with the aim of helping clinical rheumatologists to achieve better patients’ individual outcomes. We also promote basic, translational and clinical research, engaging clinicians and scientists in the common goal of expanding the frontiers of knowledge in rheumatology.
Indexed in: PubMed, PubMed Central, Google Scholar, DOAJ, Emerging Sources Citation Index, CLOCKSS
PMCID: all published articles receive a PMCID
Rheumatology welcomes submissions of the following article types: Case Report, Clinical Study Protocol, Clinical Trial, Community Case Study, Correction, Editorial, General Commentary, Hypothesis and Theory, Mini Review, Original Research, Perspective, Protocols, Review and Systematic Review.
All manuscripts must be submitted directly to the section Rheumatology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Rheumatology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Medicine.